338 related articles for article (PubMed ID: 33074304)
1. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
Knopman DS; Lundt ES; Therneau TM; Albertson SM; Gunter JL; Senjem ML; Schwarz CG; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Vemuri P; Kantarci K; Lowe VJ; Petersen RC; Jack CR;
JAMA Neurol; 2021 Feb; 78(2):217-228. PubMed ID: 33074304
[TBL] [Abstract][Full Text] [Related]
2. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Binette AP; Vogel JW; Klein G; Borroni E; Tonietto M; Strandberg O; Mattsson-Carlgren N; Palmqvist S; Pontecorvo MJ; Iaccarino L; Stomrud E; Ossenkoppele R; Smith R; Hansson O;
JAMA Neurol; 2023 Jun; 80(6):614-623. PubMed ID: 37155176
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
5. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
6. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
[TBL] [Abstract][Full Text] [Related]
7. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA
Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046
[TBL] [Abstract][Full Text] [Related]
8. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.
Ossenkoppele R; Rabinovici GD; Smith R; Cho H; Schöll M; Strandberg O; Palmqvist S; Mattsson N; Janelidze S; Santillo A; Ohlsson T; Jögi J; Tsai R; La Joie R; Kramer J; Boxer AL; Gorno-Tempini ML; Miller BL; Choi JY; Ryu YH; Lyoo CH; Hansson O
JAMA; 2018 Sep; 320(11):1151-1162. PubMed ID: 30326496
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.
Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S
JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372
[TBL] [Abstract][Full Text] [Related]
10. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
11. Cross-Sectional and Longitudinal Comparison of Tau Imaging with 18F-MK6240 and 18F-Flortaucipir in Populations Matched for Age, MMSE and Brain Beta-Amyloid Burden.
Bourgeat P; Krishnadas N; Doré V; Mulligan R; Tyrrell R; Bozinovski S; Huang K; Fripp J; Villemagne VL; Rowe CC
J Prev Alzheimers Dis; 2023; 10(2):251-258. PubMed ID: 36946452
[TBL] [Abstract][Full Text] [Related]
12. Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer's disease.
Cai Y; Du J; Li A; Zhu Y; Xu L; Sun K; Ma S; Guo T;
Alzheimers Res Ther; 2023 Feb; 15(1):30. PubMed ID: 36750884
[TBL] [Abstract][Full Text] [Related]
13. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes.
Fleisher AS; Pontecorvo MJ; Devous MD; Lu M; Arora AK; Truocchio SP; Aldea P; Flitter M; Locascio T; Devine M; Siderowf A; Beach TG; Montine TJ; Serrano GE; Curtis C; Perrin A; Salloway S; Daniel M; Wellman C; Joshi AD; Irwin DJ; Lowe VJ; Seeley WW; Ikonomovic MD; Masdeu JC; Kennedy I; Harris T; Navitsky M; Southekal S; Mintun MA;
JAMA Neurol; 2020 Jul; 77(7):829-839. PubMed ID: 32338734
[TBL] [Abstract][Full Text] [Related]
14. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.
Buckley RF; Mormino EC; Rabin JS; Hohman TJ; Landau S; Hanseeuw BJ; Jacobs HIL; Papp KV; Amariglio RE; Properzi MJ; Schultz AP; Kirn D; Scott MR; Hedden T; Farrell M; Price J; Chhatwal J; Rentz DM; Villemagne VL; Johnson KA; Sperling RA
JAMA Neurol; 2019 May; 76(5):542-551. PubMed ID: 30715078
[TBL] [Abstract][Full Text] [Related]
15. Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks.
Schumacher J; Gunter JL; Przybelski SA; Jones DT; Graff-Radford J; Savica R; Schwarz CG; Senjem ML; Jack CR; Lowe VJ; Knopman DS; Fields JA; Kremers WK; Petersen RC; Graff-Radford NR; Ferman TJ; Boeve BF; Thomas AJ; Taylor JP; Kantarci K
Brain; 2021 Nov; 144(10):3212-3225. PubMed ID: 34114602
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
[TBL] [Abstract][Full Text] [Related]
17. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
[TBL] [Abstract][Full Text] [Related]
20. Partial volume correction in longitudinal tau PET studies: is it really needed?
Costoya-Sánchez A; Moscoso A; Sobrino T; Ruibal Á; Grothe MJ; Schöll M; Silva-Rodríguez J; Aguiar P;
Neuroimage; 2024 Apr; 289():120537. PubMed ID: 38367651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
